Table 3. Multivariate analyses of OS and PFS in the POPLAR and OAK cohorts. Analyses 1 and 2 are within the atezolizumab arms and analyses 3 and 4 include both treatment arms and a treatment–test interaction.
| Cohort | Covariate | OS | PFS | |||
|---|---|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | |||
| 1. | POPLAR | Poor versus Good | 0.35 (0.22 to 0.56) | <0.001 | 0.52 (0.35 to 0.76) | 0.001 |
| ECOG PS 0 versus 1 | 1.51 (0.90 to 2.55) | 0.122 | 1.44 (0.94 to 2.21) | 0.094 | ||
| 1 versus 2 prior lines of therapy | 1.17 (0.75 to 1.83) | 0.499 | 0.89 (0.61 to 1.31) | 0.570 | ||
| PD-L1 status negative versus positive | 0.66 (0.42 to 1.03) | 0.069 | 0.77 (0.52 to 1.13) | 0.184 | ||
| Ever smoker versus never smoker | 0.72 (0.38 to 1.35) | 0.303 | 1.61 (1.00 to 2.58) | 0.049 | ||
| Squamous versus non-squamous | 0.66 (0.41 to 1.06) | 0.083 | 0.72 (0.49 to 1.07) | 0.108 | ||
| 2. | OAK | Poor versus Good | 0.55 (0.43 to 0.70) | <0.001 | 0.76 (0.62 to 0.95) | 0.013 |
| ECOG PS 0 versus 1 | 1.60 (1.24 to 2.07) | <0.001 | 1.30 (1.04 to 1.62) | 0.022 | ||
| 1 versus 2 prior lines of therapy | 0.94 (0.71 to 1.24) | 0.642 | 0.75 (0.59 to 0.97) | 0.027 | ||
| PD-L1 status negative versus positive | 0.62 (0.49 to 0.79) | <0.001 | 0.78 (0.64 to 0.97) | 0.024 | ||
| Ever smoker versus never smoker | 1.03 (0.74 to 1.44) | 0.876 | 1.59 (1.20 to 2.12) | 0.001 | ||
| Squamous versus non-squamous | 0.84 (0.64 to 1.10) | 0.208 | 1.01 (0.79 to 1.30) | 0.925 | ||
| 3. | POPLAR | Poor versus Good | 0.88 (0.60 to 1.31) | 0.535 | 1.05 (0.73 to 1.52) | 0.778 |
| Docetaxel versus atezolizumab | 1.16 (0.78 to 1.73) | 0.467 | 1.41 (0.97 to 2.05) | 0.072 | ||
| Interaction | 0.37 (0.20 to 0.68) | 0.001 | 0.47 (0.27 to 0.79) | 0.005 | ||
| ECOG PS 0 versus 1 | 1.34 (0.96 to 1.86) | 0.089 | 1.25 (0.93 to 1.67) | 0.145 | ||
| 1 versus 2 prior lines of therapy | 1.10 (0.80 to 1.50) | 0.557 | 0.97 (0.73 to 1.27) | 0.806 | ||
| PD-L1 status negative versus positive | 0.88 (0.64 to 1.20) | 0.424 | 0.94 (0.71 to 1.25) | 0.669 | ||
| Ever smoker versus never smoker | 0.66 (0.43 to 1.01) | 0.055 | 1.02 (0.71 to 1.44) | 0.935 | ||
| Squamous versus non-squamous | 0.75 (0.55 to 1.03) | 0.072 | 0.74 (0.56 to 0.99) | 0.041 | ||
| 4. | OAK | Poor versus Good | 0.58 (0.46 to 0.73) | <0.001 | 0.65 (0.52 to 0.80) | <0.001 |
| Docetaxel versus atezolizumab | 0.73 (0.58 to 0.92) | 0.008 | 0.89 (0.71 to 1.11) | 0.288 | ||
| Interaction | 0.97 (0.70 to 1.35) | 0.859 | 1.17 (0.87 to 1.57) | 0.298 | ||
| ECOG PS 0 versus 1 | 1.73 (1.45 to 2.07) | <0.001 | 1.37 (1.17 to 1.60) | <0.001 | ||
| 1 versus 2 prior lines of therapy | 0.96 (0.79 to 1.17) | 0.686 | 0.81 (0.68 to 0.97) | 0.019 | ||
| PD-L1 status negative versus positive | 0.76 (0.64 to 0.90) | 0.001 | 0.86 (0.74 to 1.00) | 0.051 | ||
| Ever smoker versus never smoker | 1.08 (0.85 to 1.37) | 0.550 | 1.47 (1.20 to 1.81) | <0.001 | ||
| Squamous versus non-squamous | 0.81 (0.67 to 0.98) | 0.029 | 0.97 (0.81 to 1.16) | 0.717 | ||
ECOG PS, Eastern Cooperative Oncology Group performance status; OS, overall survival; PD-L1, programmed cell death-ligand 1; PFS, progression-free survival.